Principal Financial Group Inc. Cuts Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Principal Financial Group Inc. trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 4.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 248,636 shares of the company's stock after selling 11,842 shares during the quarter. Principal Financial Group Inc. owned 0.50% of Prestige Consumer Healthcare worth $17,927,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Quest Partners LLC increased its position in shares of Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company's stock valued at $30,000 after acquiring an additional 424 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock valued at $35,000 after buying an additional 433 shares in the last quarter. nVerses Capital LLC lifted its stake in Prestige Consumer Healthcare by 200.0% during the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company's stock worth $43,000 after acquiring an additional 400 shares in the last quarter. Huntington National Bank grew its position in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after acquiring an additional 181 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its position in shares of Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock worth $83,000 after purchasing an additional 1,138 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Down 1.0 %

NYSE PBH traded down $0.78 during trading on Friday, reaching $78.45. 179,220 shares of the company's stock were exchanged, compared to its average volume of 251,899. The company has a 50 day moving average price of $79.85 and a two-hundred day moving average price of $73.43. The stock has a market cap of $3.88 billion, a P/E ratio of 19.09, a price-to-earnings-growth ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare Inc. has a 1 year low of $57.95 and a 1 year high of $86.36. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $283.79 million during the quarter, compared to analysts' expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm's revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 earnings per share. On average, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on PBH shares. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. DA Davidson reiterated a "buy" rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Wednesday, December 18th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $85.25.

Insider Buying and Selling

In other news, insider William P'pool sold 8,987 shares of the company's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares of the company's stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares of the company's stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 in the last ninety days. 1.60% of the stock is owned by corporate insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.